(cMPO) Myeloid cell marker, by flowcytometry, EDTA Blood

(cMPO) Myeloid Cell Marker by Flow Cytometry, EDTA Blood

Test Overview

The cMPO (Cytoplasmic Myeloperoxidase) Myeloid Cell Marker test is performed using flow cytometry to detect the presence of myeloperoxidase enzyme inside myeloid cells. It is primarily used in the diagnosis and classification of acute leukemias, especially Acute Myeloid Leukemia (AML).

Why This Test is Done

• Helps identify myeloid lineage cells
• Assists in differentiating AML from ALL
• Supports leukemia immunophenotyping
• Useful in hematological malignancy evaluation
• Helps clinicians plan targeted treatment strategies

Sample Type

• Sample: EDTA Blood

Method

• Technique: Flow Cytometry

Clinical Significance

cMPO positivity is a key marker indicating myeloid differentiation. The test is commonly included in leukemia marker panels for accurate classification and disease assessment.

Preparation

• No special preparation required
• Inform the physician about ongoing medications or prior hematological conditions

Reporting Time

• Typically available within 24–48 hours depending on laboratory workflow.